17
ALL17
KamadaYear
17
ALL5
20234
20223
20215
2020DEALS // DEV.
17
ALL9
Deals8
DevelopmentsCountry
17
ALL14
ISRAEL1
SWEDEN2
U.S.A17
ALL1
AcuCort1
Israeli Health Authorities4
Kedrion7
Not Applicable1
Saol therapeutics2
Takeda Pharmaceutical1
UndisclosedTherapeutic Area
17
ALL4
Genetic Disease2
Immunology10
Infections and Infectious Diseases1
Pulmonary/Respiratory DiseasesStudy Phase
17
ALL10
Approved1
Phase IV2
Phase III2
Phase I/ Phase II1
Discovery1
UndisclosedDeal Type
9
ALL1
Acquisition6
Agreement1
Collaboration1
Licensing AgreementProduct Type
17
ALL15
Large molecule1
Small molecule1
VaccineDosage Form
13
ALL1
Film2
Infusion1
Inhaler3
Injectable/Injection2
Injection1
Intravenous3
Solution For InfusionLead Product
17
ALL1
Alpha1-Proteinase Inhibitor1
Alpha1-Proteinase Inhibitor (Human)1
Anti-Corona (COVID-19) IgG product1
Anti-SARS-CoV-2 polyclonal immunoglobulin1
COVID-19 IgG Therapy1
Cytomegalovirus Human Immune Globulin1
Cytomegalovirus Immune Globulin [Human]1
Dexamethasone1
Human Alpha 1 Proteinase Inhibitor1
Human Alpha1-Proteinase Inhibitor1
Human Alpha1-proteinase1
Human Cytomegalovirus Immune Globulin1
Human Rabies Immune Globulin1
Plasma-derived hyperimmune globulin1
Rabies Immune Globulin (Human)1
Rabies Immune Globulin [Human]1
Varicella Zoster Immune Globulin (Human)Target
4
ALL4
Alpha-1 antitrypsin proteinLead Product(s) : Rabies Immune Globulin (Human)
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Kedrion
Deal Size : Undisclosed
Deal Type : Agreement
Details : The commercial agreement includes potential expansion of Kedrion's distribution of Kedrab, a Human Rabies Immune Globulin, in additional territories beyond the US. In addition, the two companies will collaborate to expand distribution of Kedrion products...
Brand Name : Kedrab
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 07, 2023
Lead Product(s) : Rabies Immune Globulin (Human)
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Kedrion
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Human Rabies Immune Globulin
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Kedrion
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims for the distribution of Kedrab (Rabies Immune Globulin [Human]), which is indicated for passive, transient post-exposure prophylaxis of rabies infection to persons of all ages when given immediately after contact with a rabid, in the U...
Brand Name : Kedrab
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 12, 2023
Lead Product(s) : Human Rabies Immune Globulin
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Kedrion
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Human Alpha1-Proteinase Inhibitor
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Glassia is an Alpha1 -Proteinase Inhibitor (Human), indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency of Alpha1, also known as alpha1-antitrypsin (AAT) deficien...
Brand Name : Glassia
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 16, 2023
Lead Product(s) : Human Alpha1-Proteinase Inhibitor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cytomegalovirus Human Immune Globulin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cytogam (Human cytomegalovirus) Immuno Globulin Intravenous is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart.
Brand Name : Cytogam
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 03, 2023
Lead Product(s) : Cytomegalovirus Human Immune Globulin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Human Cytomegalovirus Immune Globulin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cytogam (Human cytomegalovirus) Immuno Globulin Intravenous is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart.
Brand Name : Cytogam
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 04, 2023
Lead Product(s) : Human Cytomegalovirus Immune Globulin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Immunology
Study Phase : Approved
Recipient : AcuCort
Deal Size : Undisclosed
Deal Type : Agreement
AcuCort Signs Its First Commercial Agreement for The Company's Drug Zeqmelit™
Details : Under the terms of the agreement, Kamada is responsible for the commercialization of Zeqmelit™ (dexamethasone) in Israel and has the exclusive right to marketing, sales, and distribution of the drug in this market.
Brand Name : Zeqmelit
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 23, 2022
Lead Product(s) : Dexamethasone
Therapeutic Area : Immunology
Highest Development Status : Approved
Recipient : AcuCort
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Human Alpha1-proteinase
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF.
Brand Name : Glassia
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 07, 2022
Lead Product(s) : Human Alpha1-proteinase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Varicella Zoster Immune Globulin (Human)
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Undisclosed
Deal Size : $11.4 million
Deal Type : Agreement
Kamada Announces $11.4 Million International VARIZIG Procurement Agreement
Details : VARIZIG (Varicella Zoster Immune Globulin), one of four acquired FDA-approved commercial products by Kamada, contains antibodies specific for the Varicella zoster virus, and is indicated for post-exposure prophylaxis of varicella (chickenpox) in high-ris...
Brand Name : Varizig
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 06, 2022
Lead Product(s) : Varicella Zoster Immune Globulin (Human)
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Undisclosed
Deal Size : $11.4 million
Deal Type : Agreement
Lead Product(s) : Alpha1-Proteinase Inhibitor
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GLASSIA, is an Alpha1 -Proteinase Inhibitor (Human), indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency of Alpha1 -PI, also known as alpha1 -antitrypsin deficien...
Brand Name : Glassia
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 17, 2022
Lead Product(s) : Alpha1-Proteinase Inhibitor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cytomegalovirus Immune Globulin [Human],Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Saol therapeutics
Deal Size : $145.0 million
Deal Type : Acquisition
Details : Under the terms of the agreement, Kamada Inc., will be responsible for the commercialization of the CYTOGAM®, WINRHO®, HEPAGAM B®, and VARIZIG® in the U.S., including direct sales to wholesalers and local distributers.
Brand Name : Cytogam
Molecule Type : Large molecule
Upfront Cash : $95.0 million
November 22, 2021
Lead Product(s) : Cytomegalovirus Immune Globulin [Human],Ganciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Saol therapeutics
Deal Size : $145.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?